Skip to main content
Clinical Trials/EUCTR2019-000171-16-GB
EUCTR2019-000171-16-GB
Active, not recruiting
Phase 1

Comparison between Propofol and Inhalational Anaesthetic Agents on Cardiovascular Outcomes following Cardiac Surgery - a Randomised Controlled Feasibility Trial - COPIA

King's College Hospital NHS Foundation Trust0 sites50 target enrollmentJuly 5, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Cardiopulmonary bypass (CPB) and revascularisation-induced ischaemic reperfusion injury
Sponsor
King's College Hospital NHS Foundation Trust
Enrollment
50
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 5, 2019
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients (male and female) aged 18 years and above
  • 2\.Written informed consent to participate
  • 3\.Patients undergoing Coronary Artery Bypass Graft (CABG) surgery on Cardiopulmonary bypass (CPB) with or without valve surgery
  • 4\. Additive European System for Cardiac Operative Risk Evaluation (EuroSCORE) of 5 or higher (higher scores indicating a greater risk of death; 0 indicates minimum risk and \=6 indicates high risk)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 50
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 50

Exclusion Criteria

  • 1\.Pregnant or lactating women
  • 2\.Allergy to propofol
  • 3\.Previous diagnosis or suspected malignant hyperthermia
  • 4\. Patients with a known sensitivity to any of the IMPs or other halogenated anaesthetics
  • 5\. Concomitant therapy with Glibenclamide, Allopurinol, Theophylline or Nicorandil (medications that may interfere with remote ischemic preconditioning)
  • 6\. Inclusion in another clinical trial of an investigational medicinal product within the last 3 months.

Outcomes

Primary Outcomes

Not specified

Similar Trials